ECAT BlackRock ESG Capital Allocation Term Trust Insider Trading

Saba Capital sells 223.3K shares of ECAT for $3.5M; holdings drop -1.2% to 18.98M shares

Saba Capital Management, LP executed 2 separate sales totaling 223,318 shares for $3,514,841.92 at a blended average price of $15.74 on June 1–2, 2026. The sale reduced its 10% owner stake from 19,204,722 shares to 18,981,404 shares, a -1.2% reduction. At the transaction prices, the stock was trading near its 52-week range and the current price of $15.62 is -8.9% from the 52-week high, though the 30-day and 90-day changes show +5.0% and +5.9% gains respectively. Across Saba's cross-ticker trading history, 5 prior sells averaged 1.4% returns at both the 30-day and 90-day horizons with a 20.00% well-timed rate; at ECAT specifically, 5 prior sells show mixed results (ranging from -0.1% to +2.6% at 90 days), with 1 of 5 classified as well-timed at the 90-day mark. The modest portfolio reduction and the recent positive price momentum following prior ECAT sales suggest this is a routine rebalancing activity rather than a signal of material concern.

Saba Capital sells 208,534 shares of ECAT for $3,251,101.16 across two days at $15.54–$15.64

Saba Capital Management, LP executed 2 separate sales totaling 208,534 shares for $3,251,101.16 on 2026-05-28 and 2026-05-29, reducing holdings from 19.41M to 19.20M shares (-1.1%). The sales occurred at a blended average price of $15.59, modestly below the current price of $15.70 and 8.4% below the 52-week high of $17.14. At the same-ticker level, Saba's 5 prior ECAT trades show a 20.00% well-timed rate (1 of 5 were timed favorably), with recent sales on 2026-05-22, 2026-05-21, 2026-05-20, 2026-05-19, and 2026-05-13 returning between -0.1% and +2.6% at the 90-day mark. The insider's cross-ticker track record shows 5 prior sells with an average 90-day return of +1.4% and a 20.00% well-timed rate, indicating a pattern of selling into rises rather than declines. The current stock price is up 5.9% over 30 days and up 5.0% over 90 days, consistent with the insider's historical outcome after sells at this ticker.

Saba Capital (10% owner) sells 195,533 shares at blended $15.53; maintains 19.41M-share position in ECAT

Saba Capital Management, LP executed 2 separate sales totaling 195,533 shares for $3,036,831.31 at an average price of $15.53 on May 26-27, 2026. The sales represent a -1.0% reduction in holdings, leaving the 10% owner with 19,413,256 shares post-transaction. At the same-ticker level, Saba has executed 5 prior sales at ECAT over a 9-day window (May 13–22), of which only 1 of 5 was well-timed at the 90-day mark. Current price sits at $15.51, only 0.1% below the blended transaction price and 9.5% below the 52-week high of $17.14; the stock has gained 5.9% over the past 30 days. This sale follows a pattern of frequent, modest dispositions by the insider at this security, none of which demonstrated consistent forward-looking timing discipline across the same-ticker record.

Saba Capital Management sells 100,233 shares of ECAT in 2 transactions for $1,534,964.31; still holds 19.61M shares

Saba Capital Management, the 10% owner of BlackRock ESG Capital Allocation Term Trust, executed two separate sales on consecutive days (May 21–22, 2026) totaling 100,233 shares for $1,534,964.31 at an average price of $15.31. This represents a -0.5% reduction from the holder's pre-transaction position of 19.71M shares, leaving 19.61M shares post-sale. The current stock price of $15.50 is nearly aligned with the blended transaction price of $15.31 and sits 9.6% below the 52-week high of $17.14. Among Saba's prior five sales at ECAT, only 2 of 5 were well-timed (40% win rate at this ticker). Across all open-market activity and tickers, Saba's sell track record shows a 25% well-timed rate and a positive average 90-day return of +0.4% after sales, indicating prior sales have typically been followed by continued stock appreciation rather than declines. The modest scale of this sale relative to total holdings and the lack of any material shift in the ownership position suggest routine portfolio activity rather than a decisive conviction signal.

10% owner Saba Capital sold 69,036 shares at blended $15.13; retains 19.71M shares in ECAT closed-end fund.

Saba Capital Management filed two separate sales totaling 69,036 shares for $1,044,210.24 at an average price of $15.13 on May 19–20, 2026. The sale reduced holdings by only 0.3% (from 19.78M to 19.71M shares), leaving the 10% owner with a substantial remaining position in this BlackRock ESG closed-end fund. Current price is $15.16, modestly above the transaction prices, and the stock has recovered 4.5% over the past 30 days after declining 11.6% from its 52-week high. Across Saba's own cross-ticker track record, prior sells show only 25% well-timed outcomes and a +0.4% average 90-day return, meaning the fund's stock typically rose after the insider's sales. At this specific ticker, the insider's 5 prior sales showed mixed timing: 2 of 5 were well-timed at 90 days, suggesting inconsistent predictive signal.

Saba Capital Management, 10% ECAT holder, sells 184K shares; 7th sale in 36 months with history of poorly-timed exits.

Saba Capital Management, a 10% beneficial owner of BlackRock ESG Capital Allocation Term Trust, sold approximately 184,000 shares across two transactions in mid-May, reducing its stake from roughly 20 million shares to 19.8 million. This is the fund's seventh open-market sale at ECAT in the past three years, continuing a pattern of consistent portfolio reductions. The timing is notable: all five of Saba's prior ECAT sales saw the stock rise afterward over both the following month and quarter, indicating poor exit timing historically. The current sale occurs while the stock trades modestly below its 52-week high and has posted modest gains over the past quarter, a position that does not suggest forced or distressed liquidation. As a large institutional holder managing a fund with hundreds of open-market transactions across multiple holdings, this activity reflects routine portfolio management rather than insider conviction, and the poor historical timing of Saba's exits at this specific stock suggests the fund has struggled to pick bottoms for its reductions in ECAT.

Saba Capital Management, a 10% owner, sells 216,297 shares for $3.3M—its sixth consecutive sale in less than a week.

L.P. Saba Capital Management, holding a substantial 10% stake in ECAT, has sold shares on six consecutive trading days within a compressed timeframe, including this latest disposition of over 216,000 shares. This rapid sequence of sales is notable given the fund's filing history—while it has far more sales than purchases across its portfolio activity over the past three years, its prior exits from ECAT have all been poorly timed, with the stock rising after every previous sale at this ticker. The current sale comes as the stock trades more than 10% below its 52-week high, though it has recovered modestly in the past month. For a large institutional holder, repeated sales at this pace typically reflect portfolio rebalancing or liquidity management rather than strategic conviction about the company's direction, but the consistent pattern of ill-timed exits at this specific holding suggests the fund may be fighting headwinds in selling into strength.

L.P. Saba Capital Management (10% owner) sells 281,640 shares for $4.25M; stock trading below 52-week high after modest recent gains.

L.P. Saba Capital Management, a 10% beneficial owner of ECAT, sold approximately 281,640 shares across two trading days for a combined $4.25 million. These dispositions represent less than 1.5% of holdings, suggesting a modest portfolio adjustment rather than a significant shift in the fund's position. The stock is currently trading well below its 52-week high, having gained modestly over the past month. Notably, Saba's prior five sales at ECAT were all poorly timed—in each instance, the stock rose in the following period—and this new pair of sales continues a established pattern of institutional selling into moments when the stock subsequently climbs. The fund has been a net seller of ECAT (eleven sales versus nine buys in the broader 36-month filing history), and these latest transactions represent the fund's 884th and 885th open-market sales during that window.

Saba Capital, 10% owner of ECAT, sells ~303k shares; stock near 52-week lows, but prior exits poorly timed.

L.P. Saba Capital Management, a substantial 10% shareholder in the ESG-focused term trust, executed two sales totaling over $4.2 million in shares in early April, reducing its position by a small fraction. The stock was trading well below its 52-week high at the time, and has remained in that depressed range. However, this sale fits a troubling pattern: all five of Saba's prior sales at this ticker have been poorly timed, with the stock rising in the months following each exit. This seventh sale at the company suggests Saba continues to manage its fund allocation without demonstrating consistent foresight about the stock's direction—the firm appears to be a mechanical liquidator rather than a contrarian buyer or seller with edge. The sales themselves are modest in scale relative to Saba's holdings, indicating routine portfolio housekeeping rather than a major change in conviction.

L.P. Saba Capital Management sells ~272K shares of ECAT over two days; stock trades below recent highs after modest near-term gains.

L.P. Saba Capital Management, a 10% beneficial owner of BlackRock ESG Capital Allocation Term Trust, executed two sales totaling approximately 272,000 shares on consecutive trading days in early May, disposing of roughly one percent of its holdings. The stock is currently trading well below its recent highs, despite a notable rally over the past month. Examining Saba's prior sales in this same stock reveals a consistent pattern of poor timing: all four completed prior sales were followed by modest subsequent gains, meaning the stock rose after Saba sold each time. The most recent prior sale occurred just days before these transactions and remains too recent to evaluate. These back-to-back exits, coming after a string of poorly-timed prior sales in the same security, suggest the fund may be executing a programmatic reduction rather than responding to a sudden shift in conviction or company fundamentals. For investors holding ECAT, the pattern warrants attention—not because a single 10% owner's trades are necessarily predictive, but because institutional holders often have sophisticated monitoring frameworks that inform when they decide to trim large positions.